BIT
$8M11mo
Biotron
Biotechnology · Infectious disease
Clinical-stage biotechnology company developing small-molecule antiviral drugs targeting viroporin proteins, with lead candidate BIT225 in Phase 2 for HIV-1.
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.6M
Dec 2025 4C
Runway
11moCAUTION
Based on Dec 2025 4C
Market Cap
$8M
Burn Rate
$0.4M/qtr
Dec 2025 4C
Shares Outstanding
2.7B
Pipeline Assets
2
Latest Insight(1)
26 Feb 2026Half YearHalf Yearly Report and Accounts
Cash$1.6M·Burn$0.9M/q·OCF$-0.9M
3M Price
BIT.ASX$0.003+0.0% 3M
Low $0.002High $0.004
Pipeline Assets (2)
BIT225Hepatitis B (HBV)
PreclinicalBIT225HIV-1 reservoir eradication
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
BIT225
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
112 competitor trialsPhase 2+ · Non-ASX
Hepatitis B (Hbv)112 active trials
30 Ph420 Ph32 Ph2/345 Ph215 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)
BIT225 licensing/partnership deal (via C14 advisory)
UpcomingSpeculativearrow_upwardHigh30 June 2026
HBV preclinical efficacy data from animal models
UpcomingExpectedremoveMed30 June 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| BIT225 licensing/partnership deal (via C14 advisory) | commercial milestone | Speculative | arrow_upwardHigh | 30 June 2026 |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
Med63/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
What drove these scores · rolling 2yr
arrow_drop_down
Volatile burn rate — 100% quarterly variation — inconsistent spend
arrow_drop_up
R&D-focused spend — 100% of opex directed to R&D
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.